Core Viewpoint - The announcement indicates that Guangdong Xianfeng, a significant shareholder of Xianfeng Holdings, has been declared bankrupt, leading to the planned auction of its shares without affecting the company's control or daily operations [1] Summary by Relevant Sections Shareholder Status - Guangdong Xianfeng holds 3.1586 million shares, representing 0.31% of the total share capital of Xianfeng Holdings [1] Bankruptcy and Auction Details - The court has approved the stock disposal plan proposed by the administrator, allowing the 3.1586 million shares to be auctioned on the JD Judicial Auction platform [1] - The auction is scheduled to start on November 12, 2025, with a starting price of 3.91 yuan per share, totaling approximately 12.3503 million yuan [1] Impact on Company Operations - The disposal of shares will not result in a change of control for the company and will have no impact on its daily operations [1]

Core Insights - The animal health sector experienced a decline of 0.35% on November 3, with Reap Bio leading the losses [1] - The Shanghai Composite Index closed at 3976.52, up 0.55%, while the Shenzhen Component Index closed at 13404.06, up 0.19% [1] Stock Performance Summary - Hai Li Biological (603718) closed at 7.02, up 2.03% with a trading volume of 101,600 shares and a turnover of 70.93 million yuan [1] - Shen Lian Biological (688098) closed at 11.36, up 1.43% with a trading volume of 133,100 shares and a turnover of 150 million yuan [1] - Yong Shun Biological (920729) closed at 10.09, up 1.00% with a trading volume of 23,800 shares and a turnover of 24.09 million yuan [1] - The worst performer was Reap Bio (300119), which closed at 21.01, down 2.51% with a trading volume of 103,300 shares and a turnover of 219 million yuan [2] Capital Flow Analysis - The animal health sector saw a net outflow of 35.26 million yuan from institutional investors, while retail investors had a net inflow of 26.79 million yuan [2] - The main capital inflow was observed in Shen Lian Biological, with a net inflow of 4.03 million yuan from institutional investors [3] - Conversely, Reap Bio experienced a net outflow of 1.29 million yuan from institutional investors [3]

Core Viewpoint - The company, Xianfeng Holdings, announced that its shareholder, Shenzhen Ansheng Zhihua Investment Partnership (Limited Partnership), has committed to unconditionally and irrevocably waive all voting rights associated with its shares for a period of 12 months starting from October 31, 2025 [1] Summary by Category - **Shareholder Commitment** - Ansheng Zhihua has provided a commitment to waive all voting rights for its shares [1] - This waiver is effective for 12 months starting from October 31, 2025 [1]

Core Points - The company Xianfeng Holdings (002141.SZ) has received a commitment from its shareholder, Shenzhen Ansheng Zhihua Investment Partnership (Limited Partnership), to unconditionally and irrevocably waive all voting rights for a period of 12 months starting from October 31, 2025 [1] - During this period, Ansheng Zhihua will hold 0 shares with voting rights, while the controlling shareholder and its concerted parties collectively hold 117,310,647 shares with voting rights, accounting for 11.36% of the total voting shares of the company [1] - As of the date of the announcement, there has been no change in the control of the company [1]

证券代码：002141 证券简称：贤丰控股 公告编号：2025-078 贤丰控股股份有限公司 2.进展情况 收到《关于无条件且不可撤销放弃表决权的承诺》的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 深圳安盛致和投资合伙企业（有限合伙）承诺：自 2025 年 10 月 31 日起 12 个月内，继续无条件且不可撤销地放弃所持股份的全部表决权，期间其持有公 司有表决权的股份 0 股。控股股东及其一致行动人合计持有公司有表决权的股 份 117,310,647 股，占公司有表决权总股份的 11.36%，截至本公告日，公司控 制权尚未发生变更。 一、概述 贤丰控股股份有限公司（以下简称"公司"或"本公司"）于近日收到股东 深圳安盛致和投资合伙企业（有限合伙）（以下简称"安盛致和"或"本企业"） 出具的《关于无条件且不可撤销放弃表决权的承诺》，安盛致和承诺自 2025 年 10 月 31 日起 12 个月内，继续无条件且不可撤销地放弃所持股份的全部表决权。 二、放弃表决权的情况 1.前期情况 安盛致和前期通过京东拍卖平台获得公司股票 198,140, ...

Market Overview - The animal health sector experienced a decline of 2.79% on October 30, with Jinhe Biology leading the drop [1] - The Shanghai Composite Index closed at 3986.9, down 0.73%, while the Shenzhen Component Index closed at 13532.13, down 1.16% [1] Individual Stock Performance - Jinhe Biology (002688) closed at 6.25, down 7.13% with a trading volume of 578,000 shares and a transaction value of 367 million yuan [1] - Keqian Biology (688526) closed at 16.15, down 6.76% with a trading volume of 139,800 shares and a transaction value of 228 million yuan [1] - Maofeng Holdings (002141) closed at 3.92, down 5.08% with a trading volume of 461,300 shares and a transaction value of 18.3 million yuan [1] - Other notable declines include Dayu Biology (920970) down 2.69%, and Pulaike (603566) down 2.68% [1] Capital Flow Analysis - The animal health sector saw a net outflow of 84.7 million yuan from institutional investors, while retail investors experienced a net outflow of 16.5 million yuan [1] - Speculative funds recorded a net inflow of 101 million yuan [1] Detailed Capital Flow for Selected Stocks - Keqian Biology (688526) had a net inflow of 39.6 million yuan from institutional investors, while retail investors saw a net outflow of 60.9 million yuan [2] - Huisheng Biology (300871) experienced a net inflow of 18.3 million yuan from institutional investors, with a net outflow of 21.2 million yuan from retail investors [2] - Other stocks like Pulaike (603566) and Maofeng Holdings (002141) also reported significant net outflows from institutional investors [2]

第八届董事会第二十二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 1. 贤丰控股股份有限公司（以下简称"公司"）第八届董事会第二十二次 会议通知已提前以电话、邮件等方式发出。 2. 会议于 2025 年 10 月 29 日在子公司会议室以现场与电子通信（线上会议） 相结合的方式召开。 3. 会议应参与表决董事 7 人，实际参与表决董事 7 人（其中独立董事肖世 练先生、邓延昌先生、梁融先生以线上会议方式出席）。 4. 会议由公司董事长韩桃子女士主持。 5. 本次董事会会议的召开符合有关法律、行政法规、部门规章、规范性文 件和《公司章程》的规定。 二、董事会会议审议情况 证券代码：002141 证券简称：贤丰控股 公告编号：2025-076 贤丰控股股份有限公司 1.审议通过《2025 年三季度报告》 表决结果：以 7 票赞成、0 票反对、0 票弃权的表决结果，通过本议案。 三、备查文件 1.经与会董事签字并加盖董事会印章的董事会决议。 特此公告。 贤丰控股股份有限公司 董事会 2025 年 10 月 29 日 ...

Financial Performance - The company's operating revenue for Q3 2025 reached ¥317,579,168.94, representing a significant increase of 1,768.94% year-over-year[3] - Net profit attributable to shareholders was ¥2,096,431.70, up 154.50% compared to the same period last year[3] - The basic earnings per share (EPS) was ¥0.0409, reflecting a remarkable increase of 1,205.41% year-over-year[3] - The company experienced a 1,943.92% increase in total operating revenue for the year-to-date period, amounting to ¥931,038,585.82[7] - Total operating revenue for the period reached ¥931,038,585.82, a significant increase from ¥45,551,575.77 in the previous period, reflecting a growth of approximately 1944%[15] - The company's net profit for the current period is CNY 40,509,525.86, compared to a net loss of CNY 4,010,128.51 in the previous period[16] - Operating income for the current period is CNY 40,779,905.74, while the previous period reported an operating loss of CNY 7,126,954.79[16] - Total comprehensive income for the current period is CNY 37,300,244.52, compared to a total comprehensive loss of CNY 7,274,819.08 in the previous period[16] - The company’s basic and diluted earnings per share for the current period are both CNY 0.0412, compared to CNY 0.0015 in the previous period[16] Cash Flow and Assets - The company reported a net cash flow from operating activities of ¥11,736,833.97, an increase of 141.15% compared to the same period last year[3] - The company's cash and cash equivalents decreased to ¥48,181,048.55 from ¥402,282,535.43, a decline of approximately 88%[12] - The company reported cash and cash equivalents at the end of the period amounting to CNY 31,059,019.46, down from CNY 89,754,685.17 at the end of the previous period[19] - The company received CNY 522,460,602.05 in cash from sales of goods and services, a substantial increase from CNY 54,963,938.18 in the previous period[18] - The company incurred total cash outflows from financing activities of CNY 56,710,809.87, compared to CNY 107,881,892.37 in the previous period[19] - The company’s total cash inflow from investment activities was CNY 259,833,266.64, while cash outflow was CNY 274,891,945.42, resulting in a net cash outflow of CNY -15,058,678.78[18] Assets and Liabilities - Total assets as of September 30, 2025, were ¥1,244,457,734.77, a decrease of 15.39% from the end of the previous year[3] - Non-current assets totaled ¥369,778,581.97, down from ¥408,961,643.02, reflecting a decrease of about 10%[13] - Total liabilities decreased to ¥363,715,807.85 from ¥599,813,408.35, a decline of approximately 39%[14] - The company's total assets decreased to ¥1,244,457,734.77 from ¥1,470,823,932.83, indicating a reduction of about 15%[14] - The net loss attributable to shareholders improved to -¥375,956,585.97 from -¥419,349,894.07, showing a reduction in losses of approximately 10%[14] Shareholder Information - The total number of common shareholders at the end of the reporting period is 40,293[8] - The largest shareholder, Shenzhen Ansheng Zhihua Investment Partnership, holds 19.18% of shares, totaling 198,140,000 shares[8] - Xianfeng Holdings Group holds 11.05% of shares, totaling 114,152,000 shares, with 69,000,000 shares pledged and 114,152,000 shares frozen[8] - The top ten shareholders collectively hold significant stakes, with the first two shareholders alone accounting for over 30% of total shares[8] Research and Development - Research and development expenses rose to ¥22,741,381.65, a 181.29% increase year-over-year, driven by increased investment in the copper-clad laminate business[7] - Research and development expenses increased to ¥22,741,381.65 from ¥8,084,551.18, reflecting a growth of about 182%[15] Business Operations and Changes - The company has completed the handover of related matters with partners regarding the termination of feed production business as of the report date[9] - The company has announced plans to provide guarantees for bank loans to its subsidiaries[10] - The company has initiated a share repurchase plan for equity incentives, with a repurchase ratio reaching 1%[10] - The company has disclosed the progress of its major shareholders' bankruptcy proceedings[10] - The company has made amendments to its articles of association and business scope as part of its restructuring efforts[10] Financial Investments - The company recorded a significant increase in trading financial assets, which rose by 1,388.33% to ¥98,718,955.26 due to increased investment in financial products[7] - The company’s cash flow from investing activities showed a significant net outflow of ¥15,058,678.78, primarily due to increased investment in financial products[7]

Core Viewpoint - The animal health sector experienced a slight increase of 0.21% on October 24, with significant contributions from specific stocks, particularly Biological Shares, which led the gains [1] Market Performance - The Shanghai Composite Index closed at 3950.31, up 0.71% - The Shenzhen Component Index closed at 13289.18, up 2.02% [1] Stock Performance in Animal Health Sector - Biological Shares (600201) closed at 10.77, up 2.87% with a trading volume of 311,900 shares and a turnover of 333 million yuan - Other notable stocks include: - *ST Green Health (002868): closed at 29.09, up 0.66% - Shunlian Biological (688098): closed at 10.75, up 0.66% - Huisheng Biological (300871): closed at 20.75, up 0.48% - Yongshun Biological (920729): closed at 9.68, up 0.31% - Jinhe Biological (002688): closed at 6.68, unchanged [1] Capital Flow Analysis - The animal health sector saw a net inflow of 8.6031 million yuan from institutional investors, while retail investors experienced a net outflow of 24.4195 million yuan [2] - The breakdown of capital flow indicates: - Repu Biological (300119) had a net inflow of 9.2707 million yuan from institutional investors - Biological Shares (600201) saw a net inflow of 8.4244 million yuan - Kexin Biological (688526) had a net inflow of 5.4428 million yuan from institutional investors [3]

Core Viewpoint - The animal health sector experienced a decline of 0.36% on October 22, with Dayu Biological leading the drop. The Shanghai Composite Index closed at 3913.76, down 0.07%, while the Shenzhen Component Index closed at 12996.61, down 0.62% [1]. Stock Performance Summary - The following stocks in the animal health sector showed varied performance: - Shengwu Co. (600201) closed at 10.78, up 0.56% with a trading volume of 327,000 shares and a turnover of 351 million yuan - Ruipu Biological (300119) closed at 21.50, up 0.51% with a trading volume of 73,200 shares and a turnover of 158 million yuan - Haili Biological (603718) closed at 7.04, up 0.28% with a trading volume of 44,200 shares and a turnover of 31.17 million yuan - Dayu Biological (920970) closed at 9.46, down 1.25% with a trading volume of 20,800 shares and a turnover of 19.89 million yuan - ST Lvkang (002868) closed at 28.49, down 1.18% with a trading volume of 9,904 shares and a turnover of 28.26 million yuan [1][2]. Capital Flow Analysis - The animal health sector saw a net outflow of 47.45 million yuan from institutional investors, while retail investors contributed a net inflow of 36.66 million yuan. Speculative funds recorded a net inflow of 10.80 million yuan [2][3]. - Specific stock capital flows included: - Shunlian Biological (688098) had a net inflow of 6.94 million yuan from institutional investors but a net outflow of 12.58 million yuan from retail investors - Ruipu Biological (300119) experienced a net outflow of 2.94 million yuan from institutional investors, with a significant net inflow of 13.74 million yuan from speculative funds [3].